VINC OTC
Vincerx Pharma, Inc.
1W: -2.3%
1M: +0.0%
3M: -2.3%
YTD: -2.3%
1Y: -76.9%
3Y: -100.0%
5Y: -100.0%
$0.01
+0.00 (+1.18%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.1M
52W Range0.001-1.43
Volume2,669
Avg Volume5,083
Beta1.46
Dividend—
Analyst Ratings
Company Info
CEORaquel E. Izumi
Employees12
SectorHealthcare
IndustryBiotechnology
IPO Date2020-05-27
Websitevincerx.com
260 Sheridan Avenue
Palo Alto, CA 94306
US
Palo Alto, CA 94306
US
650 800 6676
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Haas Kevin | 0 | — | 2024-12-20 | |
| Haas Kevin | 27,875 | $0.55 | 2024-12-20 | |
| THOMAS TOM C | A-Award | 175,000 | $0.55 | 2024-08-12 |
| THOMAS TOM C | D-Return | 86,000 | $1.17 | 2024-08-12 |
| THOMAS TOM C | D-Return | 31,250 | $7.38 | 2024-08-12 |